Denny Ardhianto | Suharjono
1,2Faculty of Pharmacy, Airlangga University, Surabaya, Indonesia
Email: ardhianto.denny@gmail.com
Abstract
Migraine is a disease that is still often experienced and can reduce community productivity. The prevalence of migraine occurs in 4% – 9% in men and 11% – 25% in women. Migraine therapy is divided into preventative therapy and curative therapy. Migraine prevention therapy has recently become a new development in the world of health. The drug that has just been approved by the FDA is Fremanezumab. Fremanezumab is a CGRP antagonist, its research has entered phase III where this drug can be used in more patients. Some guidelines recommend the use of this drug as a preventative measure for migraine. In this review it can be concluded that fremanezumab can be used to prevent migraines and at least the occurrence of side effects.
Keywords: Fremanezumab, calcitonin-gene related peptide, Migraine, CGRP antagonist
